ADC Therapeutics SA (ADCT): Revenue

Annual figures by period end, from SEC filings.

$81.36M

Year ended 2025-12-31

$79.58M

Trailing 12 months to 2026-06-30

-27.1%

3-year compound annual growth

2022-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$81.36M	+14.9%	2026-03-10, From 2025-01-01
2024-12-31	$70.84M	+1.8%	2026-03-10, From 2024-01-01
2023-12-31	$69.56M	-66.9%	2025-03-27, From 2023-01-01
2022-12-31	$209.91M	n/a	2024-03-13, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
ADC Therapeutics SA (ADCT)	2025-12-31	$81.36M	+14.9%
Arcturus Therapeutics Holdings Inc. (ARCT)	2025-12-31	$82.03M	-46.1%
Eton Pharmaceuticals, Inc. (ETON)	2025-12-31	$79.95M	+104.9%
Nurix Therapeutics, Inc. (NRIX)	2025-11-30	$83.98M	+54.0%
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	$84.28M	-5.5%
Standard Biotools Inc. (LAB)	2025-12-31	$85.33M	-6.2%
CytomX Therapeutics, Inc. (CTMX)	2025-12-31	$76.20M	-44.8%
Cytokinetics Inc (CYTK)	2025-12-31	$88.04M	+376.6%
AbCellera Biologics Inc. (ABCL)	2025-12-31	$75.13M	+160.6%

Compare ADCT, ARCT, ETON, NRIX side by side · Screen every company in Pharmaceutical Preparations ↗